Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Blood|January 29, 2017
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosisGiovanni Palladini, Paolo Milani, Andrea Foli, et al.
Current HIV Research|May 16, 2009
HIV-1 plasma variants encoding truncated reverse transcriptase (RT) in a patient with high RT-specific CD8+ memory T-cell responseStefania Paolucci, Andrea Foli, Roberto Gulminetti, et al.
Haematologica|September 18, 2012
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosisGiovanni Palladini, Paola Russo, Paolo Milani, et al.
Clinical Chemistry and Laboratory Medicine|December 19, 2015
A patient with AL amyloidosis with negative free light chain resultsPaolo Milani, Veronica Valentini, Giovanni Ferraro, et al.
Blood Advances|September 4, 2020
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosisMarco Basset, Paolo Milani, Mario Nuvolone, et al.
AIDS (London, England)|July 2, 2005
Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanismsFranco Lori, Andrea Foli, Antonella Groff, et al.
Blood Cancer Journal|September 3, 2020
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapyPaolo Milani, Marco Basset, Mario Nuvolone, et al.
Haematologica|November 12, 2013
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approachGiovanni Palladini, Paolo Milani, Andrea Foli, et al.
American Journal of Hematology|March 6, 2012
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failureGiovanni Palladini, Andrea Foli, Paolo Milani, et al.
Annals of Hematology|May 3, 2011
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomideGiovanni Palladini, Paola Russo, Andrea Foli, et al.
Pageof 7